Current status of adoptive immunotherapy of malignancies

Bibliography

• ROSENBERG SA, LOTZE MT, YANG JC et al.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. Natl. Cancer Inst. (1993) 85:622–632.
   Google Scholar
• HOFFMAN DM, GITLITZ BJ, BELLDEGRUN A, FIGLIN RA: Adoptive cellular therapy. Serail]. Olga (2000) 27:221–233.
   Google Scholar
• CHILDS RW: Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma. Crit. Rev ImmunaL (2001) 21:191–203.
   PubMed Web of Science ®Google Scholar
• GRIMM EA, RAMSEY KM, MAZUMDER A, WILSON DJ, DJEU JY, ROSENBERG SA: Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. j Exp. Med. (1983) 157:884–897.
   Google Scholar
• SCHMIDT RE, MURRAY C, DALEY JF,SCHLOSSMAN SE RITZ J: A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. j Exp. Med. (1986) 164:351–356.
   PubMed Web of Science ®Google Scholar
• KOBARI M, EGAWA S, SHIBUYA K, SUNAMURA M, SAITOH K, MATSUNO S: Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. Br I Surg. (2000) 87:43–48.
   PubMed Web of Science ®Google Scholar
• HAYES RL, ARBIT E, ODAIMI M et al.: Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit. Rev Hematal. (2001) 39:31–42.
   PubMed Web of Science ®Google Scholar
• PIZZA G, DE VINCI C, LO CONTE Get al.: Immunotherapy of metastatic kidney cancer. Intl Cancer (2001) 94:109–120.
   PubMed Web of Science ®Google Scholar
• YANO T, SUGIO K, YAMAZAKI K et al.: Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer. Lung Cancer (1999) 26:143–148.
   PubMed Web of Science ®Google Scholar
• GARLIE NK, SIEBENLIST RE, LEFEVERAV: T cells activated in vitro as immunotherapy for renal cell carcinoma: characterization of 2 effector T-cell populations. J Ural. (2001) 166:299–303.
   PubMed Web of Science ®Google Scholar
• OSBAND ME, LAVIN PT, BABAYAN RK et al.: Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet (1990) 335:994–998.
   PubMed Web of Science ®Google Scholar
• GRAHAM S, BABAYAN RK, LAMM DL et al.: The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study. Strain. Ural. (1993) 11:27–34.
   PubMedGoogle Scholar
• •Report of a clinical trial that demonstrated a survival benefit for autolymphocyte therapy.
   Google Scholar
• GOLD JE, ROSS SD, KRELLENSTEIN DJ, LAROSA F, MALAMUD SC, OSBAND ME: Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients. Eur. Cancer (1995) 31A:698–708.
   PubMed Web of Science ®Google Scholar
• LUM LG, LEFEVER AV, TREISMAN JS, GARLIE NK, HANSON JP JR.: Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-Phase I clinical trial. Immunother. (2001) 24:408–419.
   Google Scholar
• SKORNICK Y, TOPALIAN S, ROSENBERG SA: Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor. Biol. Response Mod. (1990) 9:431–438.
   PubMedGoogle Scholar
• YANNELLI JR, HYATT C, MCCONNELL S etal.: Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. Cancer (1996) 65:413–421.
   Google Scholar
• ROSENBERG SA, YANNELLI JR, YANG JC et al.: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.j Natl. Cancer Inst. (1994) 86:1159–1166.
   Google Scholar
• FABBRI M, RID OLFI R, MALTONI R etal.: Tumor infiltrating lymphocytes and continuous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma. Tinnori (2000) 86:46–52.
   Google Scholar
• SEMINO C, MARTINI L, QUEIROLO P et al.: Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience. Anti-Cancer Res. (1999) 19:5645–5649.
   PubMed Web of Science ®Google Scholar
• FIGLIN RA, THOMPSON JA, BUKOWSKI RM et al: Multicenter, randomized, Phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. I Chu. Oncol (1999) 17:2521–2529.
   PubMed Web of Science ®Google Scholar
• •The largest randomised study of therapy with TILs for the treatment of RCC showing no clinical benefit.
   Google Scholar
• PLAUTZ GE, TOUHALISKY JE, SHU S: Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell lininuriol. (1997) 178:101–107.
   Web of Science ®Google Scholar
• SADEGHI N, BLACK MJ, HIER MP, SHENOUDA G, KARP SE: Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma. Arch. Otolaryngol Head Neck Surg. (1997) 123:25–30.
   PubMed Web of Science ®Google Scholar
• PLAUTZ GE, BUKOWSKI RM, NOVICK AC et al: T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology (1999) 54:617–623.
   PubMed Web of Science ®Google Scholar
• TO WC, WOOD BG, KRAUSS JC et al:Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a Phase 1 study. Arch. Otolaryngol Head Neck Surg. (2000) 126:1225–1231.
   PubMed Web of Science ®Google Scholar
• •A clinical trial demonstrating the use of draining lymph node lymphocytes for treatment of malignancies.
   Google Scholar
• CHIN CS, GRAHAM LJ, HAMAD GG, GEORGE KR, BEAR HD: Bryostatin/ ionomycin-activated T cells mediate regression of established tumors. I Surg. Res. (2001) 98:108–115.
   PubMed Web of Science ®Google Scholar
• BEAR HD, ROBERTS J, CORNELL D, TOMBES MB, KYLE B: Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial. Cancer Immunol. Irninunother. (2001) 50:269–274.
   PubMed Web of Science ®Google Scholar
• STROME SE, MARTIN B, FLIES D et al:Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma. j Irninunother. (2000) 23:430–437.
   PubMed Web of Science ®Google Scholar
• LIU J, FINKE J, KRAUSS JC, SHU S, PLAUTZ GE: Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules. Cancer Immunol. Irninunother (1998) 46:268–276.
   PubMed Web of Science ®Google Scholar
• KAGAMU H, SHU S: Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. I Immunol. (1998) 160:3444–3452.
   PubMed Web of Science ®Google Scholar
• TANAKA H, YOSHIZAWA H, YAMAGUCHI Y et al: Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. I Irninuriol. (1999) 162:3574–3582.
   Google Scholar
• SEELEY BM, BARTHEL SW, TO WC, KJAERGAARD J, SHU S, PLAUTZ GE: Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation. Otolaryngol Head Neck Surg. (2001) 124:436–441.
   PubMed Web of Science ®Google Scholar
• COHEN PA, PENG L, KJAERGAARD J et al.: T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Grit. Rev Immunol. (2001) 21:215–248.
   PubMed Web of Science ®Google Scholar
• ARUGA A, ARUGA E, CAMERON MJ, CHANG AE: Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. I Leukoc. Biol. (1997) 61:507–516.
   PubMed Web of Science ®Google Scholar
• CHANG AE, ARUGA A, CAMERON MJ et al.: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. I Chu. Oncol (1997) 15:796–807.
   PubMed Web of Science ®Google Scholar
• PLAUTZ GE, MILLER DW, BARNETT GH etal.: T cell adoptive immunotherapy of newly diagnosed gliomas. Chu. Cancer Res. (2000) 6:2209–2218.
   Google Scholar
• KIM JA, BRESLER HS, MARTIN EW JR., ALDRICH W, HEFFELFINGER M, TRIOZZI PL: Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody. Cancer (1999) 86:22–30.
   Google Scholar
• STEVENS EJ, JACKNIN L, ROBBINS PF et al.: Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. Irninuriol. (1995) 154:762–771.
   Google Scholar
• GERVOIS N, LABARRIERE N, LE GUINER S et al.: High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells. Chu. Cancer Res. (2000) 6:1459–1467.
   Google Scholar
• BULLOCK TN, MULLINS DW, COLELLA TA, ENGELHARD VH: Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice. I Immunol. (2001) 167:5824–5831.
   PubMed Web of Science ®Google Scholar
• OELKE M, MOEHRLE U, CHEN JL et al.: Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Chu. Cancer Res. (2000) 6:1997–2005.
   PubMed Web of Science ®Google Scholar
• FONTENEAU JF, LARSSON M, SOMERSAN S et al.: Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. lininuriol. Methods (2001) 258:111–126.
   Web of Science ®Google Scholar
• ••This study demonstrates that DCs loadedwith antigen are potent at stimulating T-cells for use in adoptive immunotherapy strategies.
   Google Scholar
• MONTAGNA D, MACCARIO R, LOCATELLI F et al.: Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood (2001) 98:3359–3366.
   PubMed Web of Science ®Google Scholar
• WALTER EA, GREENBERG PD, GILBERT MJ et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl. J. Med. (1995) 333:1038–1044.
   PubMed Web of Science ®Google Scholar
• ••Study demonstrating that adoptive transferof CMV-specific CTLs can prevent CMV infections following bone marrow transplantation.
   Google Scholar
• ROONEY CM, SMITH CA, NG CY et al.: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood (1998) 92:1549–1555.
   PubMed Web of Science ®Google Scholar
• ••Study demonstrating the effectiveness ofadoptive transfer of EBV-specific CTLs in prevention and treatment of EBV-associated lymphoproliferative disease.
   Google Scholar
• CHUA D, HUANG J, ZHENG B etal.: Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int. j Cancer (2001) 94:73–80.
   Google Scholar
• SCHULTZE JL, ANDERSON KC, GILLEECE MH, GRIBBEN JG, NADLER LM: A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2. Br j Haematol. (2001) 113:455–460.
   PubMed Web of Science ®Google Scholar
• KRAMER G, STEINER GE, PAIHA S et al.: Human accessory cells activate fresh, normal, tumor-distant T lymphocytes but not tumor-infiltrating T lymphocytes to lyse autologous tumor cells in a primary cytotoxic T lymphocyte assay in renal cell carcinoma. Eur. Urol. (2001) 40:427–433.
   PubMed Web of Science ®Google Scholar
• VALMORI D, PITTET MJ, RIMOLDI D et al.: An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res. (1999) 59:2167–2173.
   PubMed Web of Science ®Google Scholar
• MOLLDREM JJ, LEE PP, WANG C, CHAMPLIN RE, DAVIS MM: A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. (1999) 59:2675–2681.
   PubMed Web of Science ®Google Scholar
• SZMANIA S, GALLOWAY A, BRUORTON M et al.: Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood (2001) 98:505–512.
   PubMed Web of Science ®Google Scholar
• BROSTERHUS H, BRINGS S, LEYENDECKERS H et al: Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur. j Immurrol. (1999) 29:4053–4059.
   PubMed Web of Science ®Google Scholar
• BECKER C, POHLA H, FRANKENBERGER B et al.: Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat. Med. (2001) 7:1159–1162.
   PubMed Web of Science ®Google Scholar
• GALLOT G, VIVIEN R, IBISCH C et al.: Purification of Ag-specific T lymphocytes after direct peripheral blood mononuclear cell stimulation followed by CD25 selection. I. Application to CD4(+) or CD8(+) cytomegalovirus phosphoprotein pp65 epitope determination. j Immunol. (2001) 167:4196–4206.
   Google Scholar
• ••Report of a technique for selecting theCD25+ memory T-cells following exposure to antigen.
   Google Scholar
• CLAY TM, CUSTER MC, SACHS J, HWU E ROSENBERG SA, NISHIMURA MI: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lympocytes confers anti-tumor reactivity. Iinmurrol. (1999) 163:507–513.
   Google Scholar
• ••Description of successful transfer of atumour antigen-specific TCR gene into peripheral blood T-cells.
   Google Scholar
• KESSELS WHG, WOLKERS MC, VAN DEN BOOM MD etal.: Immunotherapy through TCR gene transfer. Nat. Immurrof (2001) 2:957–961.
   Google Scholar
• STANISLOWSKI T, VOSS R-H, LOTZ C et al.: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immurrol. (2001) 2:962–970.
   PubMed Web of Science ®Google Scholar
• ••Animal model of TCR gene transfershowing anti-tumour responses and no evidence of autoimmune responses.
   Google Scholar
• ALTENSCHMIDT U, MORITZ D, GRONER B: Specific cytotoxic T lymphocytes in gene therapy. I Ma. Med. (1997) 75:259–266.
   Web of Science ®Google Scholar
• ••A review that gives an excellent summaryof important factors in the design of single chain TCR approaches.
   Google Scholar
• JENSEN MC, CLARKE E TAN G et al.: Human T lymphocyte genetic modification with naked DNA. Ma. Ther. (2000) 1(1):49–55.
   Google Scholar
• HWU P, YANG JC, COWHERD R et al.: In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. (1995) 55:3369–3373.
   PubMed Web of Science ®Google Scholar
• ••Data on in vivo anti-tumour activity ofmurine T-cells transduced with chimeric TCRs.
   Google Scholar
• STANCOVSKI I, SCHINDLER DG, WAKS T, YARDEN Y, SELA M, ESHAR Z: Targeting of T lymphocytes to Neu/ HER2-expressing cells using chimeric single chain F17 receptors. j Immurrof (1993) 151:6577–6582.
   PubMed Web of Science ®Google Scholar
• MORITZ D, WELS W, MATTERN J, GRONER B: Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Nati Acad. Sci. USA (1994) 91:4318–4322.
   PubMed Web of Science ®Google Scholar
• HOMBACH A, HEUSER C, SIRCAR R et al.: T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology (1997) 113:1163–1170.
   PubMed Web of Science ®Google Scholar
• WEIJTENS ME, WILLEMSEN RA, VALERIO D, STAM K, BOLHUIS RL: Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. j Immurrol. (1996) 157:836–843.
   Web of Science ®Google Scholar
• MCGUINNESS RP GE Y, PATEL SD et al.: Anti-tumor activity of human T cells expressing the cc49-zeta chimeric immune receptor. Hum. Gene Ther. (1999) 10:165–173.
   Google Scholar
• GEIGER TL, NGUYEN E LEITENBERG D, FLAVELL RA: Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood (2001) 98:2364–2371.
   PubMed Web of Science ®Google Scholar
• MITSUYASU RT, ANTON PA, DEEKS SG et al.: Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood (2000) 96:785–793.
   PubMed Web of Science ®Google Scholar
• ••The first human in vivo administration ofreceptor-modified T-cells.
   Google Scholar
• GRIFFITH KD, READ EJ, CARRASQUILLO JA et al.: In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. j Nati Cancer Inst. (1989) 81:1709–1717.
   PubMed Web of Science ®Google Scholar
• POCKAJ BA, SHERRY RM, WEI JP etal.:Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer (1994) 73:1731–1737.
   Google Scholar
• DILLMAN RO, HURWITZ SR, SCHILTZ PM etal.: Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer. Cancer Biother. Radiopharm. (1997) 12:65–71.
   Google Scholar
• ECONOMOU JS, BELLDEGRUN AS, GLASPY J et al.: ha vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. ..J. Clin. Invest. (1996) 97:515–521.
   PubMed Web of Science ®Google Scholar
• CHIN Y, JANSSENS J, BLEUS J, ZHANG J, RAUS J: In vivo distribution of radio-labeled tumor infiltrating lymphocytes in cancer patients. In vivo (1993) 7:27–30.
   PubMedGoogle Scholar
• ZHU H, MELDER RJ, BAXTER LT, JAIN RK: Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res. (1996) 56:3771–3781.
   PubMed Web of Science ®Google Scholar
• KJAERGAARD J, HOKLAND ME, AGGER R, SKOVBO A, NANNMARK U, BASSE PH: Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals. Cancer Immunol Immunother. (2000) 48:550–560.
   PubMed Web of Science ®Google Scholar
• TATSUGAMI K, TAMADA K, ABE K, HARADA M, NOMOTO K: Local injections of 0K432 can help the infiltration of adoptively transferred CD8+ T cells into the tumor sites and synergistically induce the local production of Thl-type cytokines and CXC3 chemokines. Cancer Immunol Immunother. (2000) 49:361–368.
   PubMed Web of Science ®Google Scholar
• LIAO S, KHARE PD, ARAKAWA F etal.: Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein. Anti-Cancer Res. (2001) 21:1673–1680.
   Google Scholar
• IRJALA H, SALMI M, ALANEN K, GRENMAN R, JALKANEN S: Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium. j Immunol (2001) 166:6937–6943.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, AEBERSOLD P, CORNETTA K et al.: Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl. Med. (1990) 323:570–578.
   PubMed Web of Science ®Google Scholar
• BATHE OE DALYOT-HERMAN N, MALEK TR: IL-2 during in vitro priming promotes subsequent engraftment and successful adoptive tumor immunotherapy by persistent memory phenotypic CD8(+) T cells. j Immunol (2001) 167:4511–4517.
   PubMed Web of Science ®Google Scholar
• MANJUNATH N, SHANKAR P, WAN J et al.: Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. j Clin. Invest. (2001) 108:871–878.
   PubMed Web of Science ®Google Scholar
• SHRIKANT P, MESCHER MF: Controlof syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. j Immunol (1999) 162:2858–2866.
   PubMed Web of Science ®Google Scholar
• PHAN GQ, WANG E, MARINCOLA FM: T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. Expert Opin. Biol. Ther (2001) 1:511–523.
   PubMed Web of Science ®Google Scholar
• ZAKS TZ, CHAPPELL DB, ROSENBERG SA, RESTIFO NP: Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. Immunol (1999) 162:3273–3279.
   Web of Science ®Google Scholar
• VON BERNSTORFF W, VOSS M, FREICHEL S et al.: Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res. (2001) 7:925s–932s.
   Google Scholar
• DEAKIN AM, SINGH K, CROWE JS et al.: A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection methods. Clin. Exp. Immunol. (1999) 118:197–204.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE P, GINARDI AR, TINDERTL, STERNER CJ, GENDLER SJ: MUCl-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo. Clin. Cancer Res. (2001) 7:848s–855s.
   Google Scholar
• MAILLIARD RB, LOTZE MT: Dendritic cells prolong tumor-specific T-cell survival and effector function after interaction with tumor targets. Clin. Cancer Res. (2001) 7:980s–988s.
   Google Scholar
• BANSAL-PAKALA P, JEMBER AG, CROFT M: Signaling through 0X40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. (2001) 7:907–912.
   PubMed Web of Science ®Google Scholar
• THALL PE SUNG HG, CHOUDHURY A: Dose-finding based on feasibility and toxicity in T-cell infusion trials. Biometrics (2001) 57:914–921.
   PubMed Web of Science ®Google Scholar
• •This manuscript describes how typical Phase I study designs may be inappropriate for adoptive immunotherapy testing.
   Google Scholar